A central drug regulator alert has identified 44 drug samples from 37 Himachal-based firms as failing quality standards, raising concerns over commonly used medicines for blood pressure, diabetes, infections, pain, and gastric disorders.
Scope of the Alert
According to the monthly drugs alert issued by the central drugs regulator, 157 medicines and medical products manufactured across various states failed to meet prescribed quality standards. Of these, 44 samples—comprising 28% of the total—originated from 37 drug firms in Himachal Pradesh. This marks the highest number of substandard medicines from a single state in the country.
The affected firms are located in Baddi, Barotiwala, Nalagarh, Jharmajri, Kala Amb, Paonta Sahib, Parwanoo, and Una.
Drugs That Failed Quality Tests
The list of substandard drugs includes Iron Sucrose, Rabeprazole, Diclofenac, Ondansetron, and Oxytocin injections; Amoxicillin and Clavulanic Acid, Cefixime, Cefpodoxime, Telmisartan, Rosuvastatin, Atorvastatin, Gabapentin, Pregabalin, and Levocetirizine tablets; Omeprazole and Itraconazole capsules; various cough syrups; vitamin supplements; and several medications for diabetes and hypertension.
Of particular concern, four syrups, four misbranded products, and one antibiotic have been declared spurious (fake), which is considered a grossly serious defect by regulatory agencies. Quality defects in injectable and syrup-based products are viewed with greater concern as they can have a serious bearing on patient health.
Regulatory Response
State Drug Controller Dr. Manish Kapoor stated that notices are being issued to the manufacturers of these products and the process of recalling the affected batches from the market has begun. “Detailed investigations into the cases to identify the cause behind sample failure would be enquired into as patient safety is the top priority and there would be no compromise on quality standards,” he said.
The alert underscores the importance of continuous regulatory surveillance, with drug, cosmetic, and medical device samples from the market being analysed by central and state drug regulators. Samples failing quality parameters are listed as monthly alerts.
